Podcast CME Course Information

Exam: Exam 133

Issue: May 22, 2012

Learning Objectives

Nav1.7-related small fiber neuropathy: Impaired slow-inactivation and neuronal hyperexcitability

Upon completion of this podcast, the participant will be able to discuss our current understanding of Nav1.7 mutations and phenotypes associated with the mutations.

Recommended Audience

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

Core Competencies

• Medical Knowledge

Disclosures

Program Accreditation and Development Subcommittee (PADS) is responsible for reviewing and evaluating all CME programs. PADS members: Pradeep K. Sahota MD, FAAN, has nothing to disclose, Allison Brashear MD, FAAN, has received personal compensation for activities with Allergan, Merz, Ipsen and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, has received research support from Allergan, Merz, and Ipsen, J. Clay Goodman MD, FAAN, has nothing to disclose, Steven L. Lewis MD, FAAN, has received personal compensation in an editorial capacity for the journal Neurology, Barbara F. Westmoreland MD, FAAN, has nothing to disclose, Susan Rodmyre, has nothing to disclose.

Robert A. Gross, MD, PhD, FAAN has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past five years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers’ bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology.

Dr. Burns receives a stipend as Podcast Editor for Neurology® and performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc. AAN staff members editing the test (P Baskin, L Kleffman) have no disclosures. The CME Journal Editors, who have reviewed the exam, are Steven Lewis MD, who receives a stipend in his editorial capacity for Neurology, and James WM Owens Jr. MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology.

Dr. Waxman serves on the editorial boards of Clinical Neuroscience, The Neurologist, Neurobiology of Disease, Clinical Neurology and Neurosurgery, SYNAPSE, Molecular Neurobiology, Clinical Neuroscience Research, Neuron-Glia Biology, Neurotherapeutics, Trends in Molecular Medicine, Molecular Pain and Channels; served on the editorial board Journal of Neurotrauma; serves on the scientific advisory board for Brain and Nature Reviews Neurology; Editor-in-Chief of The Neuroscientist and Neuroscience Letters; Editor of The Journal of Physiology; Section Head Multiple Sclerosis, Faculty of 1000 Medicine; is or has been a consultant for Cardiome Pharmaceutical, Bristol-Myers Squibb, Vertex Pharmaceutical, ChromaCell and DaiNippon Sumitomo Pharmaceuticals; receives research support from Pfizer Inc., The Erythromelalgia Association and Department of Veterans Affairs; holds stock options in SITE ONE Research for serving on its Advisory Board and is listed as an inventor for a patent held by Yale University on the Invention of sodium channel NaV1.9. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers’ bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency. Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books 'Mild Cognitive Impairment and Early Alzheimer's Disease,' 'Dementia,' 'Handbook of Dementing Illnesses, 2nd edition' and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

The other participants have no disclosures.

CME Expiration

CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.

Accreditation

The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit™

The American Academy of Neurology designates that participants will receive 0.5 AMA PRA Category 1 CME credits™ by answering the multiple-choice questions in the online Podcast quiz.

Copyright

The American Academy of Neurology holds copyright for all materials in this exam.

Confidentiality

Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.

Hardware and Software Requirements

A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.

Start this exam